Penumbra director awarded 589 RSUs in Form 4
Penumbra director Thomas Wilder reported an equity award and updated holdings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Penumbra director Thomas Wilder reported an equity award and updated holdings. He acquired 589 shares of common stock via restricted stock units granted at no cost, which vest in four equal installments on March 31, June 30, September 30, and December 31, 2026. The filing also notes 4,506 shares held indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 589 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (3)
- F1. Restricted stock units (RSUs) vest as to 1/4 on each of March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to Mr. Wilder's continued service as director through such dates. Notwithstanding the foregoing, if the Closing (as defined in that certain Agreement and Plan of Merger, dated as of January 14, 2026, among the Issuer, Boston Scientific Corporation, a Delaware corporation, and Pinehurst Merger Sub, Inc., a Delaware corporation) occurs, any of the RSUs that remain unvested will fully vest on the Closing, subject to Mr. Wilder's continued service as director through such date.
- F2. A portion of these shares is subject to vesting.
- F3. Shares are held by the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
AI-generated analysis. How Rhea-AI works. Not financial advice.